<DOC>
	<DOCNO>NCT00442481</DOCNO>
	<brief_summary>The purpose study assess effect escitalopram sleep architecture utilize prospective design . Hypothesis : Escitalopram improve REM latency patient MDD respond clinically treatment .</brief_summary>
	<brief_title>Escitalopram Sleep Architecture Patients With Major Depressive Disorder</brief_title>
	<detailed_description>Disturbance sleep prominent symptom depressive disorder . Alterations sleep pattern depress patient include insomnia , frequent awakening , early wake-up non-refreshing sleep . Polysomnographic recording confirm report , report reduced latency first REM episode night , decrease density rapid eye movement , enhancement total percentage REM sleep , reduction deep slow wave sleep ( SWS ) increase night awakening ( Benca et al. , Classification sleep disorder ) . The effect antidepressant drug depression sleep disorder , specifically SSRIs , thoroughly research . The effect escitalopram sleep depressed patient report use retrospective design , propose protocol , suggest assess effect escitalopram sleep architecture utilize prospective design . Hypothesis : Escitalopram improve REM latency patient MDD respond clinically treatment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Patients suffer MDD , exclude depressive episode Bipolar Disorder . The depressive episode secondary general medical condition substance abuse . Ages 1865 year old . Patients receive medication must stable dosage one month enter trial , include hypnotic . Able understand sign inform consent form . Patients suffer sleep disturbance due physical condition ( COPD , sleep apnea essential insomnia precede diagnosis depression ) . Patients suffer unstable clinically significant medical condition ( cardiovascular , endocrine , nutritional , hepatic , urinary ) . Patients suffer malignancy neurodegenerative Parkinsons â€™ disease Patients suffer clinically significant psychiatric psychotic disease , judge DSMIV criterion , schizophrenia acute psychosis . Patients experience severe withdrawal symptom follow discontinuation hypnotic drug , upon entry baseline phase . History drug alcohol dependence within last year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>MDD</keyword>
	<keyword>Escitalopram</keyword>
	<keyword>Cipralex</keyword>
	<keyword>Sleep</keyword>
	<keyword>REM</keyword>
	<keyword>SWS</keyword>
	<keyword>Polysomnography</keyword>
</DOC>